{'fraction_non_alphanumeric': 0.023178807947019868, 'fraction_numerical': 0.008278145695364239, 'mean_word_length': 4.87378640776699, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Low-dose etoposide in the treatment of chronic myelomonocytic leukemia].

Two cases of chronic myelomonocytic leukemia (CMML) which were successfully treated with low dose etoposide are reported. One case was treated with oral etoposide in daily dose of 25 mg for 3d a week, another case in dose of 50 mg/day. Their white blood cell counts became normal and monocytes decreased after the treatment with etoposide. In the second case, blasts in peripheral blood disappeared and thrombocytopenia was improved. The experience of these cases suggests that low dose etoposide is an useful treatment for CMML.